nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—CYP3A4—Thiotepa—sarcoma	0.18	0.202	CbGbCtD
Linagliptin—ABCB1—Dactinomycin—sarcoma	0.145	0.162	CbGbCtD
Linagliptin—ABCB1—Mitoxantrone—sarcoma	0.129	0.145	CbGbCtD
Linagliptin—ABCB1—Vincristine—sarcoma	0.0891	0.0996	CbGbCtD
Linagliptin—ABCB1—Etoposide—sarcoma	0.0816	0.0913	CbGbCtD
Linagliptin—CYP3A4—Mitoxantrone—sarcoma	0.0776	0.0867	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—sarcoma	0.0557	0.0623	CbGbCtD
Linagliptin—CYP3A4—Vincristine—sarcoma	0.0534	0.0597	CbGbCtD
Linagliptin—CYP3A4—Etoposide—sarcoma	0.0489	0.0547	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—sarcoma	0.0334	0.0373	CbGbCtD
Linagliptin—Skin exfoliation—Thiotepa—sarcoma	0.00248	0.0253	CcSEcCtD
Linagliptin—Skin exfoliation—Etoposide—sarcoma	0.00178	0.0182	CcSEcCtD
Linagliptin—Pain in extremity—Vincristine—sarcoma	0.00167	0.017	CcSEcCtD
Linagliptin—Weight increased—Thiotepa—sarcoma	0.00148	0.0151	CcSEcCtD
Linagliptin—Infestation NOS—Thiotepa—sarcoma	0.00145	0.0148	CcSEcCtD
Linagliptin—Infestation—Thiotepa—sarcoma	0.00145	0.0148	CcSEcCtD
Linagliptin—Hyperlipidaemia—Epirubicin—sarcoma	0.00145	0.0148	CcSEcCtD
Linagliptin—Hyperlipidaemia—Doxorubicin—sarcoma	0.00134	0.0137	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Mitoxantrone—sarcoma	0.00131	0.0133	CcSEcCtD
Linagliptin—Weight increased—Mitoxantrone—sarcoma	0.00128	0.0131	CcSEcCtD
Linagliptin—Urinary tract infection—Mitoxantrone—sarcoma	0.00122	0.0124	CcSEcCtD
Linagliptin—Immune system disorder—Thiotepa—sarcoma	0.00118	0.012	CcSEcCtD
Linagliptin—Mediastinal disorder—Thiotepa—sarcoma	0.00117	0.012	CcSEcCtD
Linagliptin—Malnutrition—Thiotepa—sarcoma	0.00113	0.0116	CcSEcCtD
Linagliptin—Back pain—Thiotepa—sarcoma	0.0011	0.0112	CcSEcCtD
Linagliptin—Infestation NOS—Etoposide—sarcoma	0.00104	0.0106	CcSEcCtD
Linagliptin—Infestation—Etoposide—sarcoma	0.00104	0.0106	CcSEcCtD
Linagliptin—Mediastinal disorder—Vincristine—sarcoma	0.00104	0.0106	CcSEcCtD
Linagliptin—Skin exfoliation—Epirubicin—sarcoma	0.000998	0.0102	CcSEcCtD
Linagliptin—Cough—Thiotepa—sarcoma	0.00099	0.0101	CcSEcCtD
Linagliptin—Back pain—Vincristine—sarcoma	0.000973	0.00993	CcSEcCtD
Linagliptin—Myalgia—Thiotepa—sarcoma	0.000966	0.00985	CcSEcCtD
Linagliptin—Arthralgia—Thiotepa—sarcoma	0.000966	0.00985	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000959	0.00978	CcSEcCtD
Linagliptin—Myalgia—Dactinomycin—sarcoma	0.000959	0.00978	CcSEcCtD
Linagliptin—Back pain—Mitoxantrone—sarcoma	0.000948	0.00967	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—sarcoma	0.000923	0.00942	CcSEcCtD
Linagliptin—Infection—Thiotepa—sarcoma	0.00092	0.00938	CcSEcCtD
Linagliptin—Infection—Dactinomycin—sarcoma	0.000913	0.00931	CcSEcCtD
Linagliptin—Skin disorder—Thiotepa—sarcoma	0.000899	0.00917	CcSEcCtD
Linagliptin—Diabetes mellitus—Epirubicin—sarcoma	0.000872	0.0089	CcSEcCtD
Linagliptin—Myalgia—Vincristine—sarcoma	0.000856	0.00874	CcSEcCtD
Linagliptin—Cough—Mitoxantrone—sarcoma	0.000855	0.00872	CcSEcCtD
Linagliptin—Immune system disorder—Etoposide—sarcoma	0.000846	0.00862	CcSEcCtD
Linagliptin—Mediastinal disorder—Etoposide—sarcoma	0.000844	0.00861	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000844	0.0086	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000837	0.00854	CcSEcCtD
Linagliptin—Arthralgia—Mitoxantrone—sarcoma	0.000834	0.00851	CcSEcCtD
Linagliptin—Myalgia—Mitoxantrone—sarcoma	0.000834	0.00851	CcSEcCtD
Linagliptin—Anaphylactic shock—Vincristine—sarcoma	0.000821	0.00837	CcSEcCtD
Linagliptin—Infection—Vincristine—sarcoma	0.000816	0.00832	CcSEcCtD
Linagliptin—Diabetes mellitus—Doxorubicin—sarcoma	0.000807	0.00823	CcSEcCtD
Linagliptin—Anaphylactic shock—Mitoxantrone—sarcoma	0.0008	0.00816	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Thiotepa—sarcoma	0.000799	0.00815	CcSEcCtD
Linagliptin—Infection—Mitoxantrone—sarcoma	0.000794	0.0081	CcSEcCtD
Linagliptin—Constipation—Thiotepa—sarcoma	0.000792	0.00808	CcSEcCtD
Linagliptin—Back pain—Etoposide—sarcoma	0.000788	0.00804	CcSEcCtD
Linagliptin—Hypoglycaemia—Epirubicin—sarcoma	0.000777	0.00793	CcSEcCtD
Linagliptin—Skin disorder—Mitoxantrone—sarcoma	0.000777	0.00792	CcSEcCtD
Linagliptin—Pain in extremity—Epirubicin—sarcoma	0.000759	0.00774	CcSEcCtD
Linagliptin—DPP4—embryo—sarcoma	0.000748	0.0969	CbGeAlD
Linagliptin—Musculoskeletal discomfort—Vincristine—sarcoma	0.000748	0.00763	CcSEcCtD
Linagliptin—Urticaria—Thiotepa—sarcoma	0.000736	0.0075	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000728	0.00743	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—sarcoma	0.000719	0.00734	CcSEcCtD
Linagliptin—Cough—Etoposide—sarcoma	0.000711	0.00725	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Vincristine—sarcoma	0.000709	0.00723	CcSEcCtD
Linagliptin—DPP4—seminal vesicle—sarcoma	0.000703	0.091	CbGeAlD
Linagliptin—Constipation—Vincristine—sarcoma	0.000702	0.00716	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—sarcoma	0.000702	0.00716	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000689	0.00703	CcSEcCtD
Linagliptin—Constipation—Mitoxantrone—sarcoma	0.000684	0.00697	CcSEcCtD
Linagliptin—Hypersensitivity—Thiotepa—sarcoma	0.000682	0.00696	CcSEcCtD
Linagliptin—Nasopharyngitis—Epirubicin—sarcoma	0.000678	0.00692	CcSEcCtD
Linagliptin—Hypersensitivity—Dactinomycin—sarcoma	0.000677	0.00691	CcSEcCtD
Linagliptin—DPP4—hematopoietic system—sarcoma	0.000668	0.0865	CbGeAlD
Linagliptin—Anaphylactic shock—Etoposide—sarcoma	0.000665	0.00678	CcSEcCtD
Linagliptin—Infection—Etoposide—sarcoma	0.000661	0.00674	CcSEcCtD
Linagliptin—Skin disorder—Etoposide—sarcoma	0.000646	0.00659	CcSEcCtD
Linagliptin—DPP4—connective tissue—sarcoma	0.000643	0.0833	CbGeAlD
Linagliptin—Pancreatitis—Epirubicin—sarcoma	0.000643	0.00656	CcSEcCtD
Linagliptin—Urticaria—Mitoxantrone—sarcoma	0.000635	0.00648	CcSEcCtD
Linagliptin—Diarrhoea—Thiotepa—sarcoma	0.000634	0.00646	CcSEcCtD
Linagliptin—Diarrhoea—Dactinomycin—sarcoma	0.000629	0.00641	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—sarcoma	0.000628	0.0064	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Epirubicin—sarcoma	0.000609	0.00622	CcSEcCtD
Linagliptin—Hypersensitivity—Vincristine—sarcoma	0.000605	0.00617	CcSEcCtD
Linagliptin—Weight increased—Epirubicin—sarcoma	0.000597	0.00609	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—sarcoma	0.000595	0.00607	CcSEcCtD
Linagliptin—Hypersensitivity—Mitoxantrone—sarcoma	0.000589	0.00601	CcSEcCtD
Linagliptin—DPP4—smooth muscle tissue—sarcoma	0.000588	0.0762	CbGeAlD
Linagliptin—Infestation—Epirubicin—sarcoma	0.000585	0.00596	CcSEcCtD
Linagliptin—Infestation NOS—Epirubicin—sarcoma	0.000585	0.00596	CcSEcCtD
Linagliptin—Rash—Thiotepa—sarcoma	0.000584	0.00595	CcSEcCtD
Linagliptin—Dermatitis—Thiotepa—sarcoma	0.000583	0.00595	CcSEcCtD
Linagliptin—Headache—Thiotepa—sarcoma	0.00058	0.00592	CcSEcCtD
Linagliptin—Rash—Dactinomycin—sarcoma	0.000579	0.00591	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Etoposide—sarcoma	0.000574	0.00586	CcSEcCtD
Linagliptin—Constipation—Etoposide—sarcoma	0.000569	0.0058	CcSEcCtD
Linagliptin—Urinary tract infection—Epirubicin—sarcoma	0.000568	0.0058	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000564	0.00575	CcSEcCtD
Linagliptin—Diarrhoea—Vincristine—sarcoma	0.000562	0.00573	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—sarcoma	0.000552	0.00563	CcSEcCtD
Linagliptin—Diarrhoea—Mitoxantrone—sarcoma	0.000547	0.00558	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—sarcoma	0.000541	0.00552	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—sarcoma	0.000541	0.00552	CcSEcCtD
Linagliptin—Urticaria—Etoposide—sarcoma	0.000528	0.00539	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—sarcoma	0.000526	0.00536	CcSEcCtD
Linagliptin—Rash—Vincristine—sarcoma	0.000518	0.00528	CcSEcCtD
Linagliptin—Dermatitis—Vincristine—sarcoma	0.000517	0.00528	CcSEcCtD
Linagliptin—Headache—Vincristine—sarcoma	0.000514	0.00525	CcSEcCtD
Linagliptin—DPP4—uterus—sarcoma	0.000505	0.0653	CbGeAlD
Linagliptin—Rash—Mitoxantrone—sarcoma	0.000504	0.00514	CcSEcCtD
Linagliptin—Dermatitis—Mitoxantrone—sarcoma	0.000504	0.00514	CcSEcCtD
Linagliptin—Headache—Mitoxantrone—sarcoma	0.000501	0.00511	CcSEcCtD
Linagliptin—Hypersensitivity—Etoposide—sarcoma	0.00049	0.005	CcSEcCtD
Linagliptin—Immune system disorder—Epirubicin—sarcoma	0.000474	0.00483	CcSEcCtD
Linagliptin—Mediastinal disorder—Epirubicin—sarcoma	0.000473	0.00482	CcSEcCtD
Linagliptin—DPP4—lymphoid tissue—sarcoma	0.00047	0.0609	CbGeAlD
Linagliptin—Malnutrition—Epirubicin—sarcoma	0.000457	0.00466	CcSEcCtD
Linagliptin—Diarrhoea—Etoposide—sarcoma	0.000455	0.00464	CcSEcCtD
Linagliptin—DPP4—tendon—sarcoma	0.000442	0.0572	CbGeAlD
Linagliptin—Back pain—Epirubicin—sarcoma	0.000442	0.00451	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—sarcoma	0.000439	0.00447	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—sarcoma	0.000438	0.00446	CcSEcCtD
Linagliptin—DPP4—bone marrow—sarcoma	0.000428	0.0555	CbGeAlD
Linagliptin—Malnutrition—Doxorubicin—sarcoma	0.000423	0.00431	CcSEcCtD
Linagliptin—Rash—Etoposide—sarcoma	0.000419	0.00428	CcSEcCtD
Linagliptin—Dermatitis—Etoposide—sarcoma	0.000419	0.00427	CcSEcCtD
Linagliptin—Headache—Etoposide—sarcoma	0.000417	0.00425	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—sarcoma	0.000409	0.00417	CcSEcCtD
Linagliptin—Cough—Epirubicin—sarcoma	0.000399	0.00407	CcSEcCtD
Linagliptin—Arthralgia—Epirubicin—sarcoma	0.000389	0.00397	CcSEcCtD
Linagliptin—Myalgia—Epirubicin—sarcoma	0.000389	0.00397	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000386	0.00394	CcSEcCtD
Linagliptin—Anaphylactic shock—Epirubicin—sarcoma	0.000373	0.0038	CcSEcCtD
Linagliptin—Infection—Epirubicin—sarcoma	0.00037	0.00378	CcSEcCtD
Linagliptin—Cough—Doxorubicin—sarcoma	0.000369	0.00376	CcSEcCtD
Linagliptin—DPP4—testis—sarcoma	0.000366	0.0474	CbGeAlD
Linagliptin—Skin disorder—Epirubicin—sarcoma	0.000362	0.00369	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—sarcoma	0.00036	0.00367	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—sarcoma	0.00036	0.00367	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000357	0.00365	CcSEcCtD
Linagliptin—DPP4—liver—sarcoma	0.000346	0.0448	CbGeAlD
Linagliptin—Anaphylactic shock—Doxorubicin—sarcoma	0.000345	0.00352	CcSEcCtD
Linagliptin—Infection—Doxorubicin—sarcoma	0.000343	0.0035	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Epirubicin—sarcoma	0.00034	0.00346	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—sarcoma	0.000335	0.00342	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Epirubicin—sarcoma	0.000322	0.00328	CcSEcCtD
Linagliptin—Constipation—Epirubicin—sarcoma	0.000319	0.00325	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000314	0.00321	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000298	0.00304	CcSEcCtD
Linagliptin—Urticaria—Epirubicin—sarcoma	0.000296	0.00302	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—sarcoma	0.000295	0.00301	CcSEcCtD
Linagliptin—Hypersensitivity—Epirubicin—sarcoma	0.000275	0.0028	CcSEcCtD
Linagliptin—Urticaria—Doxorubicin—sarcoma	0.000274	0.0028	CcSEcCtD
Linagliptin—DPP4—lymph node—sarcoma	0.000265	0.0344	CbGeAlD
Linagliptin—Diarrhoea—Epirubicin—sarcoma	0.000255	0.0026	CcSEcCtD
Linagliptin—Hypersensitivity—Doxorubicin—sarcoma	0.000254	0.00259	CcSEcCtD
Linagliptin—Diarrhoea—Doxorubicin—sarcoma	0.000236	0.00241	CcSEcCtD
Linagliptin—Rash—Epirubicin—sarcoma	0.000235	0.0024	CcSEcCtD
Linagliptin—Dermatitis—Epirubicin—sarcoma	0.000235	0.0024	CcSEcCtD
Linagliptin—Headache—Epirubicin—sarcoma	0.000234	0.00238	CcSEcCtD
Linagliptin—CYP3A4—hematopoietic system—sarcoma	0.000218	0.0282	CbGeAlD
Linagliptin—Rash—Doxorubicin—sarcoma	0.000217	0.00222	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—sarcoma	0.000217	0.00222	CcSEcCtD
Linagliptin—Headache—Doxorubicin—sarcoma	0.000216	0.0022	CcSEcCtD
Linagliptin—ABCB1—myometrium—sarcoma	0.00018	0.0233	CbGeAlD
Linagliptin—ABCB1—embryo—sarcoma	0.000173	0.0224	CbGeAlD
Linagliptin—ABCB1—seminal vesicle—sarcoma	0.000162	0.021	CbGeAlD
Linagliptin—ABCB1—hematopoietic system—sarcoma	0.000154	0.02	CbGeAlD
Linagliptin—ABCB1—uterus—sarcoma	0.000116	0.0151	CbGeAlD
Linagliptin—CYP3A4—liver—sarcoma	0.000113	0.0146	CbGeAlD
Linagliptin—ABCB1—lymphoid tissue—sarcoma	0.000109	0.0141	CbGeAlD
Linagliptin—ABCB1—bone marrow—sarcoma	9.89e-05	0.0128	CbGeAlD
Linagliptin—ABCB1—testis—sarcoma	8.45e-05	0.0109	CbGeAlD
Linagliptin—ABCB1—liver—sarcoma	7.99e-05	0.0103	CbGeAlD
Linagliptin—ABCB1—lymph node—sarcoma	6.13e-05	0.00793	CbGeAlD
